Coherus BioSciences (CHRS) Tops Q2 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.13 -3.42%
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $65 million versus the consensus estimate of $56.41 million.
GUIDANCE:
Coherus BioSciences sees FY2024 revenue of $250-265 million, versus the consensus of $259.3 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- Netcapital gets second Nasdaq notice over late financial filings
- Genco Shipping amends shareholder rights agreement, extends to 2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
